Total macular volume as a potential biomarker in the assessment of anti-VEGF response in patients with diabetic macular edema: real-life data analysis

Eren Ekici; Ayşegül Koçak Altıntaş

Makale detayları

Total macular volume as a potential biomarker in the assessment of anti-VEGF response in patients with diabetic macular edema: real-life data analysis

Yazarlar:

Eren Ekici | Ayşegül Koçak Altıntaş

Yayıncı:

MediHealth Academy Yayıncılık

Ana Başlıklar:

Sağlık Kurumları Yönetimi

Dergi:

Anatolian Current Medical Journal Vol.5 Issue 1, pp.65-70

Belge Tipi:

Makale

Yayın Tarihi:

1/2023

Belge Dili:

İngilizce

Document ID (Org No.):

2001282645

pISSN:

2718-0115

Anahtar kelimeler:

Özet:

 Aim: To evaluate the functional and anatomic efficacy of intravitreal anti-vascular endothelial growth factor anti-VEGF therapy in patients with diabetic macular edema DME and investigate the association between central macular thickness CMT and total macular volume TMV in real-life settings. Material and Method: In this retrospective, observational, longitudinal study 38 eyes of 23 consecutive patients with center-involving DME were included. A loading phase of three monthly intravitreal anti-VEGF injections was initiated, followed by anti-VEGF injections if needed as per clinicians discretion. Results: Mean Early Treatment Diabetic Retinopathy Study ETDRS letters gained was 3.2 letters at month 12. The reduction in the mean of CMT and TMV were 60 μm and 1.33 mm3 respectively at the end of 12 months. Best-corrected visual acuity BCVA was negatively correlated with CMT r-0.573, p  0.01 and TMV r-0.533, p  0.01 initially. There was a statistically significant positive correlation between the CMT and the TMV initially r0.765, p  0.01 and month 12 r0.937, p  0.01. Baseline TMV was found to be more predictive of treatment response at the 9th month than baseline CMT. Conclusion: It is demonstrated that TMV may be a suitable biomarker in the assessment of treatment response of the macular region when regarded as a complete three-dimensional macular unit instead of central vertical thickness only. Although the present study contributes to a better understanding of managing DME in real-life settings, further prospective, and controlled investigations are needed.

 Aim: To evaluate the functional and anatomic efficacy of intravitreal anti-vascular endothelial growth factor anti-VEGF therapy in patients with diabetic macular edema DME and investigate the association between central macular thickness CMT and total macular volume TMV in real-life settings. Material and Method: In this retrospective, observational, longitudinal study 38 eyes of 23 consecutive patients with center-involving DME were included. A loading phase of three monthly intravitreal anti-VEGF injections was initiated, followed by anti-VEGF injections if needed as per clinicians discretion. Results: Mean Early Treatment Diabetic Retinopathy Study ETDRS letters gained was 3.2 letters at month 12. The reduction in the mean of CMT and TMV were 60 μm and 1.33 mm3 respectively at the end of 12 months. Best-corrected visual acuity BCVA was negatively correlated with CMT r-0.573, p  0.01 and TMV r-0.533, p  0.01 initially. There was a statistically significant positive correlation between the CMT and the TMV initially r0.765, p  0.01 and month 12 r0.937, p  0.01. Baseline TMV was found to be more predictive of treatment response at the 9th month than baseline CMT. Conclusion: It is demonstrated that TMV may be a suitable biomarker in the assessment of treatment response of the macular region when regarded as a complete three-dimensional macular unit instead of central vertical thickness only. Although the present study contributes to a better understanding of managing DME in real-life settings, further prospective, and controlled investigations are needed.

 Aim: To evaluate the functional and anatomic efficacy of intravitreal anti-vascular endothelial growth factor anti-VEGF therapy in patients with diabetic macular edema DME and investigate the association between central macular thickness CMT and total macular volume TMV in real-life settings. Material and Method: In this retrospective, observational, longitudinal study 38 eyes of 23 consecutive patients with center-involving DME were included. A loading phase of three monthly intravitreal anti-VEGF injections was initiated, followed by anti-VEGF injections if needed as per clinicians discretion. Results: Mean Early Treatment Diabetic Retinopathy Study ETDRS letters gained was 3.2 letters at month 12. The reduction in the mean of CMT and TMV were 60 μm and 1.33 mm3 respectively at the end of 12 months. Best-corrected visual acuity BCVA was negatively correlated with CMT r-0.573, p  0.01 and TMV r-0.533, p  0.01 initially. There was a statistically significant positive correlation between the CMT and the TMV initially r0.765, p  0.01 and month 12 r0.937, p  0.01. Baseline TMV was found to be more predictive of treatment response at the 9th month than baseline CMT. Conclusion: It is demonstrated that TMV may be a suitable biomarker in the assessment of treatment response of the macular region when regarded as a complete three-dimensional macular unit instead of central vertical thickness only. Although the present study contributes to a better understanding of managing DME in real-life settings, further prospective, and controlled investigations are needed.

 Aim: To evaluate the functional and anatomic efficacy of intravitreal anti-vascular endothelial growth factor anti-VEGF therapy in patients with diabetic macular edema DME and investigate the association between central macular thickness CMT and total macular volume TMV in real-life settings. Material and Method: In this retrospective, observational, longitudinal study 38 eyes of 23 consecutive patients with center-involving DME were included. A loading phase of three monthly intravitreal anti-VEGF injections was initiated, followed by anti-VEGF injections if needed as per clinicians discretion. Results: Mean Early Treatment Diabetic Retinopathy Study ETDRS letters gained was 3.2 letters at month 12. The reduction in the mean of CMT and TMV were 60 μm and 1.33 mm3 respectively at the end of 12 months. Best-corrected visual acuity BCVA was negatively correlated with CMT r-0.573, p  0.01 and TMV r-0.533, p  0.01 initially. There was a statistically significant positive correlation between the CMT and the TMV initially r0.765, p  0.01 and month 12 r0.937, p  0.01. Baseline TMV was found to be more predictive of treatment response at the 9th month than baseline CMT. Conclusion: It is demonstrated that TMV may be a suitable biomarker in the assessment of treatment response of the macular region when regarded as a complete three-dimensional macular unit instead of central vertical thickness only. Although the present study contributes to a better understanding of managing DME in real-life settings, further prospective, and controlled investigations are needed.

Makale detayları

Total macular volume as a potential biomarker in the assessment of anti-VEGF response in patients with diabetic macular edema: real-life data analysis

Yazarlar:

Eren Ekici | Ayşegül Koçak Altıntaş

Yayıncı:

MediHealth Academy Yayıncılık

Ana Başlıklar:

Sağlık Kurumları Yönetimi

Dergi:

Anatolian Current Medical Journal Vol.5 Issue 1, pp.65-70

Belge Tipi:

Makale

Yayın Tarihi:

1/2023

Belge Dili:

İngilizce

Document ID (Org No.):

2001282645

pISSN:

2718-0115

Aflibercept

anti-VEGF

central macular thickness

diabetic macular edema

total macular volume

Aflibercept

anti-VEGF

central macular thickness

diabetic macular edema

total macular volume

Sayı

Makale detayları

Yazarlar: Eren Ekici | Ayşegül Koçak Altıntaş

Yayıncı: MediHealth Academy Yayıncılık

Ana Başlıklar: Sağlık Kurumları Yönetimi

Dergi: Anatolian Current Medical Journal Vol.5 Issue 1, pp.65-70

Belge Tipi: Makale

Yayın Tarihi: 1/2023

Belge Dili: İngilizce

Document ID (Org No.): 2001282645

pISSN: 2718-0115

Sayı

Yazarlar:

Eren Ekici | Ayşegül Koçak Altıntaş

Yayıncı:

MediHealth Academy Yayıncılık

Ana Başlıklar:

Sağlık Kurumları Yönetimi

Dergi:

Anatolian Current Medical Journal Vol.5 Issue 1, pp.65-70

Belge Tipi:

Makale

Yayın Tarihi:

1/2023

Belge Dili:

İngilizce

Document ID (Org No.):

2001282645

pISSN:

2718-0115